Metagenomi Inc banner
M

Metagenomi Inc
NASDAQ:MGX

Watchlist Manager
Metagenomi Inc
NASDAQ:MGX
Watchlist
Price: 1.64 USD 2.5% Market Closed
Market Cap: $61.5m

Metagenomi Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Metagenomi Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
M
Metagenomi Inc
NASDAQ:MGX
Research & Development
-$109.2m
CAGR 3-Years
-96%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$9.1B
CAGR 3-Years
-12%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.7B
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$7.2B
CAGR 3-Years
-17%
CAGR 5-Years
-11%
CAGR 10-Years
-6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-15%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-13%
CAGR 5-Years
-14%
CAGR 10-Years
-12%
No Stocks Found

Metagenomi Inc
Glance View

Market Cap
61.5m USD
Industry
Biotechnology

Metagenomi Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Emeryville, California and currently employs 223 full-time employees. The company went IPO on 2024-02-09. Metagenomi, Inc. is a precision genetic medicine company. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.

MGX Intrinsic Value
2.01 USD
Undervaluation 19%
Intrinsic Value
Price
M

See Also

What is Metagenomi Inc's Research & Development?
Research & Development
-109.2m USD

Based on the financial report for Dec 31, 2024, Metagenomi Inc's Research & Development amounts to -109.2m USD.

What is Metagenomi Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-96%

Over the last year, the Research & Development growth was -16%. The average annual Research & Development growth rates for Metagenomi Inc have been -96% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett